IP Library Granted Patent US 7,632,920
Granted Patent B2
US 7,632,920 · App. 10/822,254 · Granted Dec 15, 2009

Soluble, stable form of HDM2, crystalline forms thereof and methods of use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,632,920
App. No.
10/822,254
Granted
Dec 15, 2009
Kind
B2
Abstract

The present invention discloses modified Hdm2 proteins that are soluble. In addition, the present invention discloses nucleic acids that encode the modified Hdm2 proteins of the present invention. The invention also provides crystals of modified Hdm2 proteins that are suitable for X-ray crystallization analysis. The present invention also discloses methods of using the modified Hdm2 proteins and crystals thereof to identify, select and/or design compounds that may be used as anticancer agents. The present invention further discloses compounds that bind to modified Hdm2 proteins in protein-ligand complexes.

Claims (12)

1. A purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 and SEQ ID NO: 12.

2. A compound represented by a structural formula which is selected from the group consisting of

3. A crystal comprising a complex between a polypeptide consisting of the amino acid sequence of SEQ ID NO: 10 and a compound represented by the structural formula:

wherein said crystal is in space group P2 1 2 1 2 1 and comprises unit cell dimensions a=37.999 Å, b=45.333 Å, c=63.999 Å, where α=β=Υ=90°.

4. A crystal comprising a complex between a polypeptide consisting of the amino acid sequence of SEQ ID NO: 6 and a compound represented by the structural formula:

wherein said crystal is in space group P2 1 2 1 2 1 and comprises unit cell dimensions a=41.1 Å, b=42.7 Å, c=53.777 Å, where α=β=Υ=90°.

5. The crystal of claim 3 wherein the complex in said crystal is characterized by structural coordinates set forth in Table 3.

6. The crystal of claim 4 wherein the complex in said crystal is characterized by structural coordinates set forth in Table 4.

7. The polypeptide of claim 1 comprising the amino acid sequence set forth in SEQ ID NO: 6.

8. The polypeptide of claim 1 comprising the amino acid sequence set forth in SEQ ID NO: 8.

9. The polypeptide of claim 1 comprising the amino acid sequence set forth in SEQ ID NO: 10.

10. The polypeptide of claim 1 comprising the amino acid sequence set forth in SEQ ID NO: 12.

Assignments (4)
CHANGE OF NAME Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 25, 2009
From: WANG, YAOLIN
To: SCHERING CORPORATION
Reel/Frame 023570/0463 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2004
From: HESSON, THOMAS; WINDSOR, WILLIAM T.
To: SCHERING CORPORATION
Reel/Frame 015303/0376 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2004
From: TAREMI, SHAHRIAR; XIE, GAOLIAN; DUCA, JOSE S.; STRICKLAND, COREY; MADISON, VINCENT S.; ZHANG, RUMIN; REICHERT, PAUL
To: SCHERING CORPORATION
Reel/Frame 015303/0399 →